Open Letter to The Hon. Dr. Jim Chalmers MP
A preliminary decision to block Cosette's acquisition of Mayne Pharma sets a bad precedent and would weaken Australia's capital markets.
We implore you to reconsider your recent preliminary view that the acquisition of Mayne Pharma Group Limited by Cosette Pharmaceuticals, Inc. would be contrary to the national interest.
With over a decade of experience as an active capital markets participant, we have invested in more than 500 change of control transactions of ASX listed companies.
We have serious concerns that the preliminary view has precarious implications that extend far beyond this transaction, risking the stability and integrity of our capital markets if the deal is blocked.
The preliminary decision to block Cosette's acquisition of Mayne Pharma sets a bad precedent and would weaken Australia's capital markets.
Author's summary: Bad precedent for Australia's capital markets.
More News
- Upskilling the UK AI Workforce in the age of AI
- Has the Republican Party forgotten that Fascists were our enemy in World War II? - Villages-News.com
- High Country Baking: Chocolate-cherry amaretti cookies
- Canada to fast-track $4.56bn critical minerals projects
- FTSE Rises Ahead of BoE Decision - Investomania
- Devastating Darnold powers the Seattle Seahawks past the Washington Commanders
- NFL Highlights: Chiefs @ Bills | sport.de
- Republicans Lead On Essential AI Accountability Regulations
- US Appeals Court lowers burden of proof for data breach lawsuits
- Mark Harmon returns as Leroy Jethro Gibbs in the ‘NCIS’ universe — here’s when his comeback episode drops